ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2021
Three challenging cases of infections by multidrug-resistant Serratia marcescens in patients admitted to intensive care units.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Review
- Emergence of carbapenem-resistantMicrobiology spectrum · 2025Article
- Phenotypic and in silico characterization of carbapenem-resistant Serratia marcescens clinical strains.Journal of global antimicrobial resistance · 2025Article
- Emergence of high-risk ST595 and ST640 clones of carbapenem-resistantFrontiers in microbiology · 2025Article
- Molecular epidemiology of a carbapenem-resistantFrontiers in microbiology · 2025Article
- Investigating the Antimicrobial Potential of 560 Compounds from the Pandemic Response Box and COVID Box against Resistant Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Molecular Characterization by Whole-Genome Sequencing of Clinical and EnvironmentalDiagnostics (Basel, Switzerland) · 2022Article
- Occurrence ofAntibiotics (Basel, Switzerland) · 2022Article
- First Report ofFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occurrence of multidrug-resistant Serratia marcescens strains represents a serious public health threat. The purpose here is to report three cases of carbapenem-resistant S. marcescens infections with unfavorable clinical outcomes and provide a molecular description of the antibiotic resistance determinants at a genomic level. We performed bacterial identification by VITEK 2 and MALDI-TOF. The minimal inhibitory concentrations of antimicrobials were determined according to the Clinical and Laboratory Standards Institute guidelines, except for tigecycline, for which they were determined using Etest strips. Preliminary screening for the presence of carbapenemases was performed by ertapenem hydrolysis using MALDI-TOF MS. Whole-genome sequencing was provided to identify genes responsible for virulence and antimicrobial resistance. Here we report three challenging cases of S. marcescens that were resistant to the most commonly used antibiotics. Otherwise, we performed a genome description, which includes several genes involved in the resistance and virulence. These cases illustrate serious infection due to multidrug-resistant organisms and the complexity of treatment. Our results highlight the need to evaluate isolates regularly during long-term hospital stay to achieve optimal quality of clinical care and thus improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.